Stockscreener 앱 받기
0.859
0.32%
0.0027
전일 마감가:
$0.8563
열려 있는:
$0.851
하루 거래량:
134.00K
Relative Volume:
0.57
시가총액:
$4.87M
수익:
-
순이익/손실:
$-6.78M
주가수익비율:
-0.0201
EPS:
-42.6996
순현금흐름:
$-4.67M
1주 성능:
-9.46%
1개월 성능:
-12.35%
6개월 성능:
-41.70%
1년 성능:
-20.46%
1일 변동 폭
$0.80
$0.899
1주일 범위
$0.80
$0.97
52주 변동 폭
$0.80
$2.30
Clearmind Medicine Inc Stock (CMND) Company Profile
CMND을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.859 | 4.87M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Clearmind Medicine Inc. (NASDAQ:CMND) Shares Acquired by Citadel Advisors LLC - Defense World
# Clearmind Medicine hires lobbying firm to advance psychedelic therapy By Investing.com - Investing.com South Africa
# Clearmind Medicine hires lobbying firm to advance psychedelic therapy - Investing.com Australia
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics - The Manila Times
Clearmind Medicine Partners with Leading Government Affairs Firm to Advance Psychedelic Therapeutics - Nasdaq
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic ... - Bluefield Daily Telegraph
Clearmind Medicine Announces Enrollment Of First Patient In Phase I/Iia Clinical Trial For Alcohol Use Disorder Treatment - marketscreener.com
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment - The Manila Times
Clearmind Medicine Inc. Begins Phase I/IIa Trial for CMND-100 to Treat Alcohol Use Disorder - Nasdaq
symbol__ Stock Quote Price and Forecast - CNN
Longeveron® to Attend BIO International Convention 2025 - TradingView
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc. - Nasdaq
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times
Stocks Under $1 To Watch: $NITO, $SPRC, $PNPNF, $NCNA, $PRSO – Multi-Sectors Momentum Building more inside… - FinancialContent
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
Clearmind Medicine files patent for eating disorder treatment - Investing.com
SciSparc and Clearmind file patent for eating disorder treatment - Investing.com
Clearmind Medicine files patent for eating disorder treatment By Investing.com - Investing.com South Africa
SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India
Psychedelic: Clearmind completes clinical site initiations for AUD trial - Yahoo Finance
SciSparc and Clearmind File Patent for Eating Disorder Treatment - TipRanks
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - The Manila Times
SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire
Clearmind Medicine Inc. Files International Patent for Novel Treatment of Eating Disorders Using 3-MMC and PEA - Nasdaq
Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites - The Manila Times
Clearmind Medicine Inc. Initiates Patient Enrollment for Phase I/IIa Clinical Trial in Alcohol Use Disorder - Nasdaq
Clearmind Medicine (NASDAQ:CMND) Stock Price Down 4.8% – Here’s Why - Defense World
Clearmind Medicine Inc (CMND) requires closer examination - uspostnews.com
Clearmind Medicine Inc Inc. (CMND) Price Performance and Its Relation to the Tech Industry - investchronicle.com
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - TradingView
Clearmind Medicine to Host Live Webinar 'Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - The Manila Times
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading - Bluefield Daily Telegraph
Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge Behavior - marketscreener.com
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior - TradingView
Clearmind Medicine Launches First U.S. Clinical Site For FDA-Approved Alcohol Use Disorder Trial - Nasdaq
Clearmind Medicine begins phase I/IIa trial for AUD treatment - Investing.com
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism - The Manila Times
Clearmind Medicine Inc. Initiates Phase I/IIa Clinical Trial for CMND-100 in Alcohol Use Disorder at Johns Hopkins University - Nasdaq
Clearmind Medicine Launches First U.S. Clinical Site For Its FDA-Approved Clinical Trial To Combat Alcoholism - MarketScreener
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial - Yahoo Finance
Clearmind Medicine (CMND) Launches U.S. Clinical Trial for Alcoh - GuruFocus
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder - The Manila Times
Clearmind Medicine files patent for new psychedelic compounds - Investing.com
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders - The Manila Times
Clearmind Medicine stock hits 52-week low at $0.95 By Investing.com - Investing.com South Africa
Clearmind Medicine stock hits 52-week low at $0.95 - Investing.com Australia
Clearmind Medicine Inc (CMND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):